QualityStocks

[QualityStocks]

CD International Enterprises, Inc. (CDII) Science turns Anecdotal Evidence into Opportunity

In a landmark new study, The New England Journal of Medicine just confirmed what thousands have attested to anecdotally for years (http://dtn.fm/zTW93). Cannabidiol, which is found in marijuana plants, dramatically reduces the number of convulsive seizures in children with a severe and often fatal epilepsy disorder. Dravet syndrome is a rare, genetic form of epilepsy diagnosed when otherwise healthy infants start having unexplained seizures. The syndrome is a complex childhood drug-resistant disorder with uncontrollable seizures and a high mortality rate. Recurrent grand mal seizures, sometimes dozens even hundreds a month, literally take over and convulse the entire body. Most patients don’t live to reach adulthood and of those who do, most are unable to live independently.

The results of this latest study follow a sweeping 400-page report released in January by the National Academies of Science, Engineering, and Medicine which covered more than 10,000 scientific studies on marijuana and medicine. The far reaching report reached multiple conclusions, among those, the firm verification that marijuana does have legitimate medical uses. The report’s resulting conclusions are supported by high-quality scientific studies that show cannabis and cannabinoids are effective at treating chronic pain, particularly pain related to multiple-sclerosis, also, that cannabinoid substances were effective for treating chemotherapy-related nausea and vomiting in cancer patients.

Cannabidiol, also called CBD, is one of more than 80 active cannabinoid chemicals in the marijuana plant, which unfortunately is classified as a Schedule I controlled substance by the federal government. Unlike tetrahydrocannabinol, or THC, CBD does not produce euphoria or a high, and multiple states have legalized its medicinal use. Anecdotal no more, two major studies released in the last four months have scientifically validated the efficacy of medicinal marijuana. To hear some tell it, the flood gates of hell have opened to allow this scourge of a drug credibility in this country. Those who suffer give thanks for access to their medicine.

With medical efficacy questions put to bed, smart money is now looking for avenues to profit from this explosive new medical market. With a projected 60 percent annual growth rate in the U.S. alone, it makes sense to look globally and to population density for an even stronger strategic play.

CD International Enterprises, Inc. (OTC: CDII), a diverse U.S.-based company with multiple global business relationships, has effectively sourced and delivered various industrial commodities to its clients in the People’s Republic of China for over 15 years. CDII’s extensive international experience and relationships give it the uncommon ability to identify and capitalize on emerging global market opportunities. The company recently formed a new division to distribute and sell medicinal CBD-based products to the 2+ billion Chinese-speaking people located around the globe. More than two billion people is one heck of a target market, and CDII has abundant knowledge of the innate practices of the Chinese consumer and Chinese commerce, which gives it competitive advantages in this fast developing global industry.

The company has already formed its new Green Products division and online retail store for CBD-based products (http://www.greencbdproducts.com/cbd). CBD oil is legal in China, and CBD-based products fit well with traditional Chinese holistic medicine. CDII believes the demand in Chinese-speaking communities for CBD-based products will easily exceed expectations. Looks like science has turned anecdotal evidence into opportunity.

Learn more about the company, its subsidiary, mineral trading and consulting divisions, and growing online CBD products store by going to http://www.cdii.net.